A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Summary

This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH. The study may be conducted in up to 2 dosing cohorts.

Timeline

Start

2019-05-17

Primary completion

2020-01-20

Completion

2020-01-20

Outcome

Outcome not reported

Stopped (Business): “sponsor decision”

Drugs

Indications